載入中
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
前收盤價
US$1.42
+US$0.03 · +2.16%
盤中時間採用ET。市場資料可能有所延遲。
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
日內區間
目前US$1.42
52週區間
目前US$1.42
盤中時間採用ET。市場資料可能有所延遲。
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
日內區間
目前US$1.42
52週區間
目前US$1.42
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 669.05萬 USD | 2563 USD | 750.62萬 USD | 674.99萬 USD | 1.3萬 USD |
| 毛利 | −669.05萬 USD | −2563 USD | −750.62萬 USD | −674.99萬 USD | −1.3萬 USD |
| 研究與開發 | 180.9萬 USD | 225.42萬 USD | 824.36萬 USD | 633.8萬 USD | 161萬 USD |
| 銷售、一般及管理費用 | — | 493.21萬 USD | — | 674.6萬 USD | 492.8萬 USD |
| 營業費用 | 180.9萬 USD | 718.63萬 USD | 824.36萬 USD | 633.77萬 USD | 621.8萬 USD |
| 利息收入 | 3.21萬 USD | 5473 USD | — | — | — |
| 利息支出 | 47.39萬 USD | 88.36萬 USD | 105.33萬 USD | 9.67萬 USD | — |
| 折舊和攤銷 | 1820 USD | 2563 USD | 3866 USD | 3797 USD | 2331 USD |
| 營業利益 | −849.96萬 USD | −718.89萬 USD | −1574.97萬 USD | −1308.76萬 USD | −623.1萬 USD |
| 淨利 | −894.97萬 USD | −470.63萬 USD | −1682.55萬 USD | −1327.2萬 USD | −543.1萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
